GAM
VRTX icon

Griffin Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Griffin Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
6,142
-33
-0.5% -$14.6K 0.32% 73
2026
Q1 		$2.76M Sell
6,175
-20
-0.3% -$9.33K 0.31% 78
2025
Q4 		$2.81M Sell
6,195
-25
-0.4% -$10.8K 0.3% 82
2025
Q3 		$2.44M Sell
6,220
-188
-3% -$78.6K 0.27% 85
2025
Q2 		$2.85M Sell
6,408
-1,609
-20% -$741K 0.34% 81
2025
Q1 		$3.89M Sell
8,017
-115
-1% -$53.6K 0.48% 59
2024
Q4 		$3.27M Sell
8,132
-581
-7% -$269K 0.38% 67
2024
Q3 		$4.05M Buy
8,713
+15
+0.2% +$7.21K 0.45% 61
2024
Q2 		$4.08M Sell
8,698
-105
-1% -$45.6K 0.47% 57
2024
Q1 		$3.68M Sell
8,803
-157
-2% -$66.4K 0.44% 63
2023
Q4 		$3.65M Buy
8,960
+132
+1% +$48.8K 0.46% 64
2023
Q3 		$3.07M Buy
8,828
+40
+0.5% +$14K 0.44% 66
2023
Q2 		$3.09M Hold
8,788
– – 0.42% 68
2023
Q1 		$2.77M Sell
8,788
-416
-5% -$125K 0.39% 70
2022
Q4 		$2.66M Sell
9,204
-363
-4% -$111K 0.4% 71
2022
Q3 		$2.77M Sell
9,567
-55
-0.6% -$15.8K 0.46% 65
2022
Q2 		$2.71M Sell
9,622
-8
-0.1% -$2.14K 0.43% 65
2022
Q1 		$2.51M Buy
9,630
+1,951
+25% +$463K 0.33% 76
2021
Q4 		$1.69M Buy
7,679
+805
+12% +$157K 0.21% 107
2021
Q3 		$1.25M Hold
6,874
– – 0.16% 127
2021
Q2 		$1.39M Buy
6,874
+1,480
+27% +$310K 0.17% 124
2021
Q1 		$1.16M Buy
5,394
+1,650
+44% +$362K 0.15% 129
2020
Q4 		$885K Buy
3,744
+129
+4% +$29.6K 0.12% 133
2020
Q3 		$984K Sell
3,615
-165
-4% -$45.5K 0.15% 117
2020
Q2 		$1.1M Sell
3,780
-30
-0.8% -$8.13K 0.18% 106
2020
Q1 		$907K Buy
+3,810
New +$874K 0.17% 105
2019
Q3 		– Sell
-613
Closed -$112K – 473
2019
Q2 		$112K Buy
+613
New +$107K 0.01% 291

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Griffin Asset Management's VRTX Position: Q2 2026 in Review

Griffin Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.53% in Q2 2026, selling an estimated $14.6K and leaving 6,142 shares worth $3.05M. The position accounts for 0.32% of the portfolio, ranked #73.

Griffin Asset Management first reported a position in VRTX in Q2 2019 and has held it in 27 quarters since. The position peaked at $4.08M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Griffin Asset Management held 6,142 shares of Vertex Pharmaceuticals worth $3.05M as of Q2 2026.
  • Griffin Asset Management sold 33 Vertex Pharmaceuticals shares in Q2 2026, an estimated $14.6K.
  • Vertex Pharmaceuticals made up 0.32% of Griffin Asset Management's portfolio in Q2 2026, its #73 holding.
  • Griffin Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • Griffin Asset Management's Vertex Pharmaceuticals position peaked at $4.08M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Griffin Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.